Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study.
Botzenhardt S, Felisi M, Bonifazi D, Del Vecchio GC, Putti MC, Kattamis A, Ceci A, Wong ICK, Neubert A; DEEP consortium (collaborative group). Botzenhardt S, et al. Among authors: del vecchio gc. Haematologica. 2018 Jan;103(1):e1-e4. doi: 10.3324/haematol.2017.176065. Epub 2017 Oct 27. Haematologica. 2018. PMID: 29079595 Free PMC article. No abstract available.
The Italian multiregional thalassemia registry: Centers characteristics, services, and patients' population.
Conte R, Ruggieri L, Gambino A, Bartoloni F, Baiardi P, Bonifazi D, Bonifazi F, Felisi M, Giannuzzi V, Padula R, Pepe A, Putti MC, Del Vecchio GC, Maggio A, Filosa A, Iacono A, Mangiarini L, Ceci A. Conte R, et al. Among authors: del vecchio gc. Hematology. 2016 Aug;21(7):415-24. doi: 10.1080/10245332.2015.1101971. Epub 2016 Feb 22. Hematology. 2016. PMID: 26863102 Free article.
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, Sherief L, Christou S, Cosmi C, Della Pasqua O, Del Vecchio GC, Filosa A, Cuccia L, Hassab H, Kreka M, Origa R, Putti MC, Spino M, Telfer P, Tempesta B, Vitrano A, Tsang YC, Zaka A, Tricta F, Bonifazi D, Ceci A. Maggio A, et al. Among authors: del vecchio gc. Lancet Haematol. 2020 Jun;7(6):e469-e478. doi: 10.1016/S2352-3026(20)30100-9. Lancet Haematol. 2020. PMID: 32470438 Clinical Trial.
Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.
Bellanti F, Del Vecchio GC, Putti MC, Maggio A, Filosa A, Cosmi C, Mangiarini L, Spino M, Connelly J, Ceci A, Della Pasqua O; Consortium DEferiprone Evaluation in Paediatrics (DEEP). Bellanti F, et al. Among authors: del vecchio gc. Br J Clin Pharmacol. 2017 Mar;83(3):593-602. doi: 10.1111/bcp.13134. Epub 2016 Nov 6. Br J Clin Pharmacol. 2017. PMID: 27641003 Free PMC article. Clinical Trial.
Model-Based Optimisation of Deferoxamine Chelation Therapy.
Bellanti F, Del Vecchio GC, Putti MC, Cosmi C, Fotzi I, Bakshi SD, Danhof M, Della Pasqua O. Bellanti F, et al. Among authors: del vecchio gc. Pharm Res. 2016 Feb;33(2):498-509. doi: 10.1007/s11095-015-1805-0. Epub 2015 Nov 10. Pharm Res. 2016. PMID: 26555666 Free PMC article.
81 results